NZ signs deal to purchase new Covid-19 treatment

Molnupiravir is the first oral antiviral treatment for Covid to report clinical trial results. Photo: Merck.

New Zealand is one of the first countries in the world to secure a deal for the new Covid-19 treatment molnupiravir.

Pharmac and Prime Minister Jacinda Ardern announced the agreement this morning. Pharmac says the oral antiviral drug would be used to treat New Zealanders with mild to moderate Covid-19 symptoms.

The agreement with supplier Merck Sharp & Dohme is subject to the drug being approved by Medsafe.

An initial supply of 60,000 courses will be sent to New Zealand after Medsafe approves the drug, Pharmac chief executive Sarah Fitt says in a statement.

"MSD recently announced trial results showing that molnupiravir considerably reduced hospitalisations and deaths from Covid-19. While these are interim results, they are very promising," Fitt says.

Ardern says New Zealand is among the first countries in the world to sign an advanced purchase agreement for the drug.

"Antiviral medicines are an additional tool the government is adding to our toolbox to fight Covid-19," Ardern says.

"The most important thing people can do to prevent themselves, children and vulnerable people getting Covid is to get vaccinated. However it's important we have medicines to help those who pick up the virus to avoid having to go to hospital.

"We are continuing to use a stamp it out strategy. But this purchase of 60,000 courses is based on the same population basis as the likes of Australia and Singapore, and is not an assumption about the level of Covid we may have in the future."

Australia's government announced last week it had purchased 300,000 courses of the drug.

Ardern says it's thanks to the "speed and hard work" of Pharmac's team that New Zealand is able to secure the treatment so quickly.

Fitt says Pharmac is proactively engaging global pharmaceutical companies to secure access to treatments.

"We have changed the way we operate, using separate funding allocated by government, to make sure that New Zealand can access new Covid-19 treatments," she says.

"Covid-19 is a unique health crisis and for this reason we are doing things differently."

Pharmac is working on securing other Covid-19 treatments, Fitt says.

Ardern says she's hopeful there will be further announcements soon as Pharmac's negotiations conclude.

-RNZ

4 comments

All well and good...

Posted on 11-10-2021 11:56 | By morepork

But not if it means we can't fund other treatments. How many people reading this have been denied access to drugs that could save their lives or ameliorate their suffering, because it isn't funded by Pharmac? They have my heartfelt sympathy. We should not be so blinded by Covid that we start thinking it is the ONLY problem our health service has to contend with.


This worries me.

Posted on 11-10-2021 12:17 | By morepork

A drug that is named after Thor's hammer, and is being subjected to an intensive marketing campaign around the world. They are so excited to get it, that some of the clinical trials were cut short so it could be approved. That's all Ballyhoo, but the thing that really worries me is the WAY that it works. It changes the RNA replication in the virus, so that it introduces "mistakes" into virus reproduction. That would be fine as long as it ONLY affects VIRAL replication. It is very attractive to the Government because it can reduce need for hospitalization if taken in the early stages of infection. At $700 a dose, it is not cheap, but still less than a hospital stay. So, we are looking at an untried, Government friendly, improperly tested, expensive drug, and we are amongst the first to sign up for it. Cross your fingers....


Yeah right.

Posted on 11-10-2021 12:55 | By Justin T.

Is this the same spin as when Ms Ardern said "we are at the front of the que for the Phizer vaccine"?


Profiteering

Posted on 11-10-2021 15:25 | By Walbuck

Hmmmm Molnupiravir - $1008 NZD per dose - and still no liability for adverse effects vs Stromectol - $3 a dose now that the Patent has expired - Proven safe over 46 years and proven effective in 28 Peer Reviewed studies - Hard to trust big Pharma Wonder if my comment will be censored ?


Leave a Comment


You must be logged in to make a comment.